Inflammasome as a new therapeutic target for diabetic complications

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 10, Issue 1, 2016, Pages 56-62

  Volpe, Caroline M O ^a   Anjos, Paula M F ^a   Nogueira Machado, José A ^a  

^a Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

DAMP; Diabetes; Inflammasome; Inflammation; Innate immunity; PAMP

Indexed keywords

INFLAMMASOME; INFLAMMASOME NLRP3; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; CRYOPYRIN; NLRP3 PROTEIN, HUMAN;

ARTICLE; DIABETES MELLITUS; EVALUATION STUDY; HUMAN; INFLAMMATORY DISEASE; PATENT; PRIORITY JOURNAL; ANIMAL; BLOOD; DIABETIC COMPLICATION; DRUG DEVELOPMENT; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNITY, INNATE; INFLAMMASOMES; MOLECULAR TARGETED THERAPY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PATENTS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 85007574698     PISSN: 18722148     EISSN: 22123334     Source Type: Journal    
DOI: 10.2174/1872214810666160219163314     Document Type: Article

References (70)

1. Feng Y, Chao W. Toll-like receptors and myocardial inflammation. Int J Inflam 2011; 2011: 1703-52.
2. Latz E, Xiao T.S, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13(6): 397-411.
3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140(6): 805-20.
4. Bianchi M.E. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007; 81(1): 1-5.
5. Janeway C.A, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
6. Bertin J. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem 1999; 274(19): 12955-8.
7. Inohara N. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem 1999; 274(21): 14560-7.
8. Ogura, Y. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276(7): 4812-8.
9. Ting JP. The NLR gene family: A standard nomenclature. Immunity 2008; 28(3): 285-7.
10. Yeretssian G. Effector functions of NLRs in the intestine: innate sensing, cell death, and disease. Immunol Res 2012; 54(1-3): 25-36.
11. Allen I.C. Characterization of NLRP12 during the in vivo host immune response to Klebsiella pneumoniae and Mycobacterium tuberculosis. PLoS One 2013; 8(4): e60842.
12. Broz P, Monack D.M. Molecular mechanisms of inflammasome activation during microbial infections. Immunol Rev 2011; 243(1): 174-90.
13. Correa RG, Milutinovic S, Reed JC. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep 2012; 32(6): 597-608.
14. Fernandes-Alnemri T. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458(7237): 509-13.
15. Chen GY. Role of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis. Eur J Immunol 2014; 44(2): 321-7.
16. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010; 10(12): 826-37.
17. Agostini L. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20(3): 319-25.
18. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: Host cell death and inflammation. Nat Rev Microbiol 2009; 7(2): 99-109.
19. Martinon, F. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237-41.
20. Sutterwala FS. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24(3): 317-27.
21. Duncan JA. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASCcontaining inflammasome. J Immunol 2009; 182(10): 6460-9.
22. Halle A. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9(8): 857-65.
23. He X. Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol 2010; 184(10): 5743-54.
24. Kapetanovic R, Bokil NJ, Sweet MJ. Innate immune perturbations, accumulating DAMPs and inflammasome dysregulation: A ticking time bomb in ageing. Ageing Res Rev 2015; 24: 40-53.
25. Mariathasan S. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440(7081): 228-32.
26. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318(20): 1315-21.
27. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 2003; 26(5): 1589-96.
28. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3): 257-67.
29. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27(3): 813-23.
30. Acosta JC. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013; 15(8): p. 978-90.
31. Chung KW. Age-related sensitivity to endotoxin-induced liver inflammation: Implication of inflammasome/IL-1beta for steatohepatitis. Aging Cell 2015; 14(4): 524-33.
32. Feldman N, Rotter-Maskowitz A, Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res Rev 2015; 24: 29-39.
33. Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev 2015; 265(1): 63-74.
34. Youm YH. Canonical Nlrp3 inflammasome links systemic lowgrade inflammation to functional decline in aging. Cell Metab 2013; 18(4): 519-32.
35. Youm YH. The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep 2012; 1(1): 56-68.
36. Li L, Liu Y. Aging-related gene signature regulated by Nlrp3 predicts glioma progression. Am J Cancer Res 2015; 5(1): 442-9.
37. Lukens JR, Dixit VD, Kanneganti TD. Inflammasome activation in obesity-related inflammatory diseases and autoimmunity. Discov Med 2011; 12(62): 65-74.
38. Lin L, Knowlton AA. Innate immunity and cardiomyocytes in ischemic heart disease. Life Sci 2014; 100(1): 1-8.
39. Villarreal-Calderon R. Intra-city differences in cardiac expression of inflammatory genes and inflammasomes in young urbanites: A pilot study. J Toxicol Pathol 2012; 25(2): 163-73.
40. Gagliani N. Inflammasomes and intestinal homeostasis: regulating and connecting infection, inflammation and the microbiota. Int Immunol 2014; 26(9): 495-9.
41. Liu Z. Role of inflammasomes in host defense against Citrobacter rodentium infection. J Biol Chem 2012; 287(20): 16955-64.
42. Anders H.J, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22(6): 1007-18.
43. Vilaysane A. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010; 21(10): 1732-44.
44. Mezzaroma E. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 2011; 108(49): 19725-30.
45. De Zoete MR. Inflammasomes. Cold Spring Harb Perspect Biol 2014; 6(12): a016287.
46. Fang L. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol 2015; 12(3): 305-12.
47. Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 2014; 55(2): 101-5.
48. Dinarello CA, Donath, MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17(4): 314-21.
49. Spranger J. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52(3): 812-7.
50. Goossens GH. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 2012; 50(3): 142-9.
51. Lee HM. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62(1): 194-204.
52. Gao P. NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia. J Diabetes Res 2015; 2015: 504-761.
53. Cassel SL. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008; 105(26): 9035-40.
54. Eisenbarth SC. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453(7198): 1122-6.
55. Kahlenberg JM, Dubyak GR. Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release. J Leukoc Biol 2004; 76(3): 676-84.
56. Kim SM. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 2015; 308(9): F993-F1003.
57. Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: Sailing between Scylla and Charybdis. Diabetes 2014; 63(11): 3569-71.
58. Ruscitti P. Monocytes from patients with Rheumatoid Arthritis and Type 2 Diabetes Mellitus display an increased production of IL-1beta via the NLRP3-inflammasome activation. A possible implication for therapeutic decision in these patients. Clin Exp Immunol 2015.
59. Nogueira-Machado JA, Chaves MM. From hyperglycemia to AGERAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients. Expert Opin Ther Targets 2008; 12(7): 871-82.
60. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
61. Cardozo AK. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005; 54(2): 452-61.
62. Sheedy FJ. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013; 14(8): 812-20.
63. Verma G, Datta M. IL-1beta induces ER stress in a JNK dependent manner that determines cell death in human pancreatic epithelial MIA PaCa-2 cells. Apoptosis 2010; 15(7): 864-76.
64. Westermark P, Andersson A, Westermark G.T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011; 91(3): 795-826.
65. Klen J, Goričar K, Janež A, Dolžan V. NLRP3 inflammasome polymorphism and macrovascular complications in Type 2 Diabetes patients. J Diabetes Res 2015; 2015: 616-747.
66. Yan Y. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 2015; 160(1-2): 62-73.
67. Schertzer, J., Steinberg, G., Tarnopolsky, M. Combination of a statin with an inflammasome inhibitor. WO2015003246 (2015).
68. Nakahata, T., Saito, M., Tanaka, T., Yamanaka, S. Method for screening drugs for suppressing inflammasome activity. US20130273588 (2013).
69. Arditi, M., Shimada, K. Mitochondrial apoptosis-induced inflammation. WO2012016145 (2012).
70. Rongbin, Z., Wei, J., Yiqingm, Y. DRD1 protein and application of agonists of DRD1 protein in preparation of medicine for treating related inflammatory diseases of NLRP3 inflammasome CN104258398 (2015).